Abu Dhabi's Public Health Centre has entered a two-year agreement with Ultrahuman to build and clinically validate a Biological Health Age model that merges laboratory biomarkers with continuous wearable data on cardiovascular function, sleep, metabolism and recovery. The stated aim is earlier identification of chronic disease trajectories, which would require the measure to outperform conventional risk tools such as blood pressure and lipid panels. For longevity medicine, the project tests an assumption the field has largely accepted without proof: that biological age can be measured accurately enough, at population scale, to alter clinical decisions.
Key Points
- Two-year government partnership validates biological age against clinical outcomes
- Model combines lab biomarkers with continuous wearable cardiovascular and sleep data
- All participant data remains within the emirate under clinical governance
Longevity Analysis
A biological age estimate sold to a consumer and one commissioned by a health ministry serve different masters; only the second must demonstrate that it identifies who develops heart disease or diabetes, and earlier than existing screening already does. The risk is circularity, since a composite assembled from established cardiometabolic markers may simply relabel what those markers already predict. The more durable contribution is the longitudinal record itself: years of continuous physiological signals from circulation, metabolic output and overnight recovery, tied to documented clinical endpoints in the same population, which is precisely the evidence base geroscience lacks and which no short trial can generate.
Original published by Longevity.Technology, by Eleanor Garth.